CN1686321A - Ant ginseng medicinal wine - Google Patents
Ant ginseng medicinal wine Download PDFInfo
- Publication number
- CN1686321A CN1686321A CNA2005100461598A CN200510046159A CN1686321A CN 1686321 A CN1686321 A CN 1686321A CN A2005100461598 A CNA2005100461598 A CN A2005100461598A CN 200510046159 A CN200510046159 A CN 200510046159A CN 1686321 A CN1686321 A CN 1686321A
- Authority
- CN
- China
- Prior art keywords
- examples
- radix
- ant
- ginseng
- effective rate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000208340 Araliaceae Species 0.000 title claims abstract description 18
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 title claims abstract description 18
- 235000003140 Panax quinquefolius Nutrition 0.000 title claims abstract description 18
- 235000008434 ginseng Nutrition 0.000 title claims abstract description 18
- 241000222336 Ganoderma Species 0.000 claims abstract description 8
- 241001251068 Formica fusca Species 0.000 claims description 9
- 239000009636 Huang Qi Substances 0.000 claims description 7
- 239000002994 raw material Substances 0.000 claims description 5
- 210000004185 liver Anatomy 0.000 abstract description 11
- 210000003734 kidney Anatomy 0.000 abstract description 9
- 210000004369 blood Anatomy 0.000 abstract description 5
- 239000008280 blood Substances 0.000 abstract description 5
- 229940107666 astragalus root Drugs 0.000 abstract 1
- 230000007812 deficiency Effects 0.000 abstract 1
- 210000001503 joint Anatomy 0.000 abstract 1
- 239000000463 material Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 43
- 201000010099 disease Diseases 0.000 description 23
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 23
- 208000024891 symptom Diseases 0.000 description 13
- 239000003814 drug Substances 0.000 description 9
- 208000011580 syndromic disease Diseases 0.000 description 9
- 239000007788 liquid Substances 0.000 description 7
- 238000000034 method Methods 0.000 description 6
- 238000005325 percolation Methods 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- 208000006820 Arthralgia Diseases 0.000 description 5
- 208000002193 Pain Diseases 0.000 description 5
- 230000002950 deficient Effects 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 239000000796 flavoring agent Substances 0.000 description 4
- 235000019634 flavors Nutrition 0.000 description 4
- 206010020751 Hypersensitivity Diseases 0.000 description 3
- 208000026935 allergic disease Diseases 0.000 description 3
- 230000007815 allergy Effects 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 201000003068 rheumatic fever Diseases 0.000 description 3
- 206010003694 Atrophy Diseases 0.000 description 2
- 208000000857 Hepatic Insufficiency Diseases 0.000 description 2
- 208000032912 Local swelling Diseases 0.000 description 2
- 208000001647 Renal Insufficiency Diseases 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 230000037444 atrophy Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 210000003414 extremity Anatomy 0.000 description 2
- 206010016256 fatigue Diseases 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- 210000003127 knee Anatomy 0.000 description 2
- 238000012856 packing Methods 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000035935 pregnancy Effects 0.000 description 2
- 239000002002 slurry Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 206010063659 Aversion Diseases 0.000 description 1
- 108010074051 C-Reactive Protein Proteins 0.000 description 1
- 102100032752 C-reactive protein Human genes 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 206010061372 Streptococcal infection Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 210000000593 adipose tissue white Anatomy 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000000550 effect on aging Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000002607 hemopoietic effect Effects 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 206010029410 night sweats Diseases 0.000 description 1
- 230000036565 night sweats Effects 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 239000011505 plaster Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
A medical wine for treating sore joint and weakness caused by deficiency of Qi and blood in liver and kidney is prepared from 9 Chinese-medicinal materials including black ant, ginseng, astragalus root, ganoderma, etc.
Description
Technical field
The present invention relates to a kind of joint aches that the Liver and kidney insufficiency of vital energy and blood causes that is used for the treatment of, the medicated wine of diseases such as fatigue and weakness has good auxiliary curative effect to treatment rheumatic arthritis.
Background technology
In all chronic arthromyodynia illness, the most common with rheumatism and arthritis.Its symptom is joint cold type of pain, limbs profound grief, local swelling, local fear of cold, pain alleviated while getting warmth, pain increase in intensity under coldness, wasting and atrophy of muscle, joint stuffiness, soreness of the waist and knees etc., brings a lot of inconvenience to live and work, has had a strong impact on quality of life.At present the above-mentioned illness of treatment is mainly come anti-inflammatory analgesic with Western medicine, can not treating both the principal and secondary aspects of a disease, and recurrence easily.The Chinese medicine such as the plaster that also have can play short run effect, but effect also are not very desirable, and can cause certain influence to skin.
Summary of the invention
The purpose of this invention is to provide a kind of taking convenience, improve the medicated wine of good, the safe and reliable auxiliary treatment of rheumatic arthritis of clinical symptoms.
Ant ginseng medicinal wine is characterized in that this medicated wine is made up of the raw material of following weight parts: Formica fusca 40-60 part, Radix Ginseng 10-30 part, Radix Astragali 20-40 part, Ganoderma 10-20 part, Fructus Lycii 20-40 part, Radix Polygoni Multiflori 10-30 part, Fructus Mori 30-50 part, Radix Et Caulis Acanthopanacis Senticosi 30-50 part, Fructus Chaenomelis 10-30 part.
The method for making of above-mentioned ant ginseng medicinal wine is: above nine flavors, get Formica fusca, smash into the Formica fusca slurry after freezing to pieces, place percolator with the coarse powder of Radix Ginseng, the Radix Astragali, Ganoderma, Fructus Lycii, Radix Polygoni Multiflori, Fructus Mori, Radix Et Caulis Acanthopanacis Senticosi, Fructus Chaenomelis eight flavor medicines,, make solvent with 40 degree Chinese liquor according to the percolation under fluid extract and the extractum item, flood after 48 hours, with the speed of per minute 1-3ml percolation slowly, collect the liquid of just filtering, with other container preservation; Continue percolation, collect the continuous liquid of filtering, being evaporated to relative density is that 1.25-1.31, temperature are 60-65 ℃ clear paste, merges with the liquid of just filtering, and adds sucrose, after the dissolving, adjusts total amount with Chinese liquor, stirs evenly, and leaves standstill 48 hours, filter, and packing, promptly.
Character: this product is the liquid of rufous; The gas sweet-smelling, little suffering of distinguishing the flavor of, sweet, little hardship.
Function cures mainly: invigorating the liver and kidney, replenishing QI and blood, channels sootheing and network vessel quickening.Be used for arthromyodynia and belong to the joint aches that the Liver and kidney insufficiency of vital energy and blood causes, the auxiliary treatment of diseases such as fatigue and weakness.
Usage and dosage: oral, a 15ml, 2 times on the one.
Taboo: hypertension, cardiac, anemia of pregnant woman and ethanol allergy sufferers are avoided usefulness.
Attention: suggestion is used under physician guidance.
Specification: every bottled 100ml, 250ml, 500ml
Storage: sealing, put shady and cool place.
Advantage of the present invention is evident in efficacy, short treating period, instant effect, has no side effect.
The specific embodiment
[clinical data]
1, physical data
Observation group's clinic case 80 examples, inpatient's 20 examples, totally 100 examples; Matched group clinic case 47 examples, inpatient's 13 examples, totally 60 examples.In observation group's 100 examples, each 50 example of men and women, mean age 43.68-10.31 year; Maximum 65 years old, minimum 20 years old; Average course of disease 4.18 ± 4.49 years, the course of disease is the longest 30 years, and is the shortest 2 months.In matched group 60 examples, male 22 examples, women 38 examples, 41.05 ± 10.20 years old mean age, maximum 64 years old, minimum 19 years old; Average course of disease 5.67 ± 6.05 years, the course of disease is the longest 26 years, and is the shortest 3 months.
Observation group and matched group patient be at aspects such as age, the course of disease, the state of an illness, learns the difference of handling that there are no significant by statistics.
2, diagnostic criteria
The Chinese medical discrimination standard
1) cold-damp resistance network disease
Cardinal symptom: joint cold type of pain, limbs are heavy.
Minor symptom: local swelling, local fear of cold, light red tongue is fat, white, slippery and moist fur is greasy, stringy and tense pulse or string slow.
Diagnosis: see that it is that cold-damp hinders network disease that two of primary symptoms, 3 of inferior diseases can be examined.
2) Liver and kidney two deficient syndromes
Cardinal symptom: muscle arthralgia, soreness of the waist and knees, joint joint stuffiness.
Minor symptom: local enlargement, wasting and atrophy of muscle, aversion to cold and preference for warmth, hands and feet being not warm, hectic fever, spontaneous perspiration, night sweat, red tongue with a little fluid, light red tongue whiten, thready and weak pulse, thready and rapid pulse.
Diagnosis: seeing that two of primary symptoms, 3 of inferior diseases can be examined is Liver and kidney two deficient syndromes.
The Western medicine diagnose standard
1) the streptococcal infection medical history is arranged more.
2) acute stage, can occur multiple and the migration joint aches, mostly occurs in the joint, can accompany red and swollen pain or tuberosity, or erythema.
3) chronic phase, only felt joint aches.
4) laboratory examination:
1. anti-" O " is more than 1: 500.
2. or erythrocyte sedimentation rate speed.
3. or antistreptokinase surpass more than 80 units.
4. or antihyaluronidase more than 128 units.
5. or the c reactive protein positive.
3, test case standard
Include the case standard in
1) meet above-mentioned in, the Western medicine diagnose standard.
2) age is the 18-65 volunteer in year.
Discharge the case standard
1) age＜18 year old,＞65 years old person.
2) women of gestation, age of sucking and preparation gestation.
3) maybe may be to ethanol allergy to certain the medicine allergy sufferers in this agent.
4) merge to have the inclination, serious diseases such as cerebrovascular, liver, kidney and hemopoietic system; The psychotic.
5) can't judge the infull person of curative effect or data.
3, observation and administrated method
1) adopt the table of random numbers to divide into groups to the experimenter, to guarantee observation group and matched group harmony at sex, age, the course of disease, state of an illness aspects.Wherein, observation group's 100 examples (cold-damp resistance network disease 50 examples, Liver and kidney two deficient syndromes 20 examples), matched group 60 examples.Clinic case should strict control variable factor.
2) medicated wine of the present invention is taken by observation group, each 15ml, and every day 2 times is oral.Matched group is taken the FENGSHI YE of being produced by Luzhou pharmaceutcal corporation, Ltd.Each 15ml, every day 2 times is oral.
3) inactive other medicine of viewing duration.
4) 4 weeks were a course of treatment, all observed a course of treatment.The symptom after taking medicine situation of change writes down once weekly.
4, curative effect determinate standard
Produce effects: reduced more than 2/3 (containing 2/3) the treatment back preceding symptom integral of treatment;
Effectively: 1/3-2/3 (containing 1/3) is reduced in the treatment back preceding symptom integral of treatment;
Invalid: the treatment back preceding symptom integral of treatment is reduced below 1/3.
5, observed result
Observation group's produce effects 61 examples, effective 34 examples, invalid 5 examples, obvious effective rate is 61%, total effective rate is 95%; Matched group produce effects 10 examples, effective 44 examples, invalid 6 examples, obvious effective rate is 16.7%, total effective rate 90%.Total effective rate observation group is higher than matched group, but there was no significant difference, P＞0.05; And the obvious effective rate aspect, observation group obviously is better than matched group, difference and significantly between the two, P＜0.01.See table 1 for details:
Table 1: observation group and matched group curative effect are relatively
| Group | The example number | Produce effects example (%) | Effectively routine (%) | Invalid example (%) | Total effective rate (%) | The P value |
| Observation group's matched group | ??100 ??60 | ????61(61) ????10(16.7) | ??34(34) ??44(73.3) | ????5(5) ????6(10) | ????95 ????90 | ????＞0.05 |
Curative effect is relatively between two kinds of pattern of syndrome of observation group:
Two kinds of pattern of syndrome of observation group are cold-damp group network and Liver and kidney two empty each 50 example.Cold-damp group network disease produce effects, effective, invalid routine number are 27,20 and 3 examples, and obvious effective rate is 54%, and total effective rate is 94%; Liver and kidney two deficient syndrome produce effects, effective, invalid routine number are 34,14 and 2 examples, and obvious effective rate is 68%, and total effective rate is 96%.Two disease type curative effects are there was no significant difference relatively, and P＞0.05 illustrates that two pattern of syndrome are the indication of medicated wine of the present invention.See table 2 for details.
Table 2: curative effect relatively between two kinds of pattern of syndrome of observation group
| The disease type | The example number | Produce effects example (%) | Effectively routine (%) | Invalid example (%) | Total effective rate (%) | The P value |
| Cold-damp group network disease Liver and kidney two deficient syndromes | ????50 ????50 | ????27(54) ????34(68) | ??20(40) ??14(28) | ????3(6) ????2(4) | ????94 ????96 | ????＞0.05 |
Observation group's course of disease and therapeutic effect relationship compare:
The course of disease is divided into 4 time limits, and entirely be produce effects with interior person's 5 examples half a year; More than or equal to half a year, and within 1 year person's 10 examples, 9 routine produce effects, 1 example effectively; More than or equal to 1 year, and in 3 years with interior person's 47 examples, produce effects 31 examples, effective 16 examples.Preceding 3 time limit patients' curative effect is absolutely.More than or equal to 3 years person's 38 examples, produce effects 16 examples, effective 17 examples, invalid 5 examples.Compare with preceding 3 time limit patient curative effects, all have can't be obtained, particularly compare with the 3rd time limit patient, both have significant difference between the total effective rate, P＜0.05.See table 3 for details.
Table 3: observation group's course of disease and therapeutic effect relationship are relatively
| Group | The example number | Produce effects example (%) | Effectively routine (%) | Invalid example (%) | Total effective rate (%) |
| ＜0.5 year 〉=0.5 year and＜1 year 〉=1 year and＜3 years 〉=3 years | ????5 ????10 ????47 ????38 | ????5(100) ????9(100) ????31(66.0) ????16(42.1) | ? ????1(10) ????16(34.0) ????17(44.7) | ? ? ? ?5(13.2) | ????100 ????100 ????100 ????86.8 |
Compare P＜0.05 with 〉=3 years course of disease groups.
Observation group's course of treatment and therapeutic effect relationship are relatively
As can be seen from Table 5, in 1 week, curative effect is not seen by observation group; Just there are 5 examples to obtain effect in 2 weeks.To 3 weekends, the variation of matter appears in curative effect, and total effective rate reaches 85%, compares with preceding 2 all curative effects, and difference is extremely remarkable.Clothes to 4 weekends, obvious effective rate reaches 61%, and total effective rate then reaches 955, and is remarkable with curative effect comparing differences in 3 weeks, P＜0.05.Then the obvious effective rate between two weeks is compared, and difference is extremely obvious, P＜0.01.Illustrating that the curative effect and the course of treatment are proportionate is, and is optimum with the curative effect around the.
Table 4: observation group's course of treatment and therapeutic effect relationship are relatively
| The course of treatment | The example number | Produce effects example (%) | Effectively routine (%) | Invalid example (%) | Total effective rate (%) |
| Around the 3rd week of second week first week the | ????100 ????100 ????100 ????100 | ? ? ????1(1) ????61(61) | ????5(5) ????84(84) ????34(34) | ????100 ????95 ????15 ????5 | ? ????5 ????85 ????95 |
Compare P＜0.05 with the 3rd week.
Observation group's sex and therapeutic effect relationship be relatively: in male's 50 examples, produce effects, effective, invalid be 30,18,2 examples, total effective rate is 96%; Women's 50 examples, produce effects, effective, invalid be 31,16,3 examples, total effective rate is 94%.Curative effect compares there was no significant difference, P＞0.05 between the men and women.Illustrate that medicated wine of the present invention is not subjected to the restriction of sex, men and women patient all can take.
Observation group's age and therapeutic effect relationship be relatively: the experimenter is equally divided into 4 age intervals, 18-29 year 9 examples, produce effects 6 examples, effective 3 examples; 30-41 year 32 examples, produce effects 17 examples, effective 13 examples, invalid 2 examples; 42-53 year 41 examples, produce effects 31 examples, effective 9 examples, invalid 1 example; 54-65 year 18 examples, produce effects 7 examples, effective 9 examples, invalid 2 examples.From total effective rate, the good more tendency of the more little curative effect of has age, but each age group patient curative effect relatively there are no significant difference, all P＞0.05.
6, toxic and side effects and untoward reaction
The patient of observation group does not see any toxic and side effects and untoward reaction at period in a medicine.Blood, urine and liver function detect, and relatively, abnormal change do not occur before and after the treatment.
7, conclusion
Clinical observation result shows, medicated wine of the present invention is a kind of taking convenience, improve the health product of good, the safe and reliable auxiliary treatment of rheumatic arthritis of clinical symptoms.
Further narrate the formulation ratio and the method for making of ant ginseng medicinal wine of the present invention below with embodiment.
Embodiment 1:
Ant ginseng medicinal wine, this medicated wine is made up of following raw material: Formica fusca 50g, Radix Ginseng 20g, Radix Astragali 30g, Ganoderma 20g, Fructus Lycii 30g, Radix Polygoni Multiflori 20g, Fructus Mori 40g, Radix Et Caulis Acanthopanacis Senticosi 40g, Fructus Chaenomelis 20g.
The method for making of described ant ginseng medicinal wine, it is characterized in that: by said ratio, get Formica fusca, smash into the Formica fusca slurry after freezing to pieces, place percolator with Radix Ginseng, the Radix Astragali, Ganoderma, Fructus Lycii, Radix Polygoni Multiflori, Fructus Mori, Radix Et Caulis Acanthopanacis Senticosi, Fructus Chaenomelis eight flavor coarse powder, use percolation, make solvent with 40 degree Chinese liquor, flood after 48 hours, with the speed of per minute 1-3ml percolation slowly, collect the about 850ml of liquid that just filters, preserve with other container; Continue percolation, collect the continuous liquid 1000ml that filters, be evaporated to relative density and be 1.25-1.31, temperature 60-65 ℃ clear paste, liquid merges with just filtering, add sucrose 100g, after the dissolving, adjusting total amount with Chinese liquor is 1000ml, stirs evenly, left standstill 48 hours, and filtered, packing, promptly.
Embodiment 2:
Ant ginseng medicinal wine, this medicated wine is made up of following raw material: Formica fusca 40g, Radix Ginseng 10g, Radix Astragali 30g, Ganoderma 20g, Fructus Lycii 30g, Radix Polygoni Multiflori 30g, Fructus Mori 30g, Radix Et Caulis Acanthopanacis Senticosi 40g, Fructus Chaenomelis 30g.
Method for making is with embodiment 1.
Embodiment 3:
Ant ginseng medicinal wine, this medicated wine is made up of following raw material: Formica fusca 60g, Radix Ginseng 20g, Radix Astragali 40g, Ganoderma 10g, Fructus Lycii 40g, Radix Polygoni Multiflori 10g, Fructus Mori 50g, Radix Et Caulis Acanthopanacis Senticosi 50g, Fructus Chaenomelis 10g.
Method for making is with embodiment 1.
Claims (1)
1, ant ginseng medicinal wine is characterized in that this medicated wine is made up of the raw material of following weight parts: Formica fusca 40-60 part, Radix Ginseng 10-30 part, Radix Astragali 20-40 part, Ganoderma 10-20 part, Fructus Lycii 20-40 part, Radix Polygoni Multiflori 10-30 part, Fructus Mori 30-50 part, Radix Et Caulis Acanthopanacis Senticosi 30-50 part, Fructus Chaenomelis 10-30 part.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005100461598A CN1274340C (en) | 2005-03-29 | 2005-03-29 | Ant ginseng medicinal wine |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005100461598A CN1274340C (en) | 2005-03-29 | 2005-03-29 | Ant ginseng medicinal wine |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1686321A true CN1686321A (en) | 2005-10-26 |
| CN1274340C CN1274340C (en) | 2006-09-13 |
Family
ID=35304363
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2005100461598A Expired - Fee Related CN1274340C (en) | 2005-03-29 | 2005-03-29 | Ant ginseng medicinal wine |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1274340C (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101798558A (en) * | 2010-03-17 | 2010-08-11 | 东莞市天邦神叶食品有限公司 | Ant and ginseng wine |
| CN102895348A (en) * | 2012-11-08 | 2013-01-30 | 成都中医药大学 | Pharmaceutical compositions for treating rheumatic joint disease, preparation method thereof and use thereof |
| CN107970326A (en) * | 2018-01-22 | 2018-05-01 | 白山市金潮特产有限责任公司 | A kind of compound mountain ant powder piece and preparation method thereof |
-
2005
- 2005-03-29 CN CNB2005100461598A patent/CN1274340C/en not_active Expired - Fee Related
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101798558A (en) * | 2010-03-17 | 2010-08-11 | 东莞市天邦神叶食品有限公司 | Ant and ginseng wine |
| CN102895348A (en) * | 2012-11-08 | 2013-01-30 | 成都中医药大学 | Pharmaceutical compositions for treating rheumatic joint disease, preparation method thereof and use thereof |
| CN102895348B (en) * | 2012-11-08 | 2014-07-30 | 成都中医药大学 | Pharmaceutical compositions for treating rheumatic joint disease, preparation method thereof and use thereof |
| CN107970326A (en) * | 2018-01-22 | 2018-05-01 | 白山市金潮特产有限责任公司 | A kind of compound mountain ant powder piece and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1274340C (en) | 2006-09-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN115837065A (en) | Traditional Chinese medicine composition and application thereof | |
| CN104491695A (en) | Pharmaceutical composition for treating chloasma | |
| CN1159050C (en) | Compound traditional Chinese medicine preparation for treating type 2 diabetes | |
| CN1274340C (en) | Ant ginseng medicinal wine | |
| CN106310040B (en) | A kind of Chinese medicine composition and its preparation method and application for treating acute gouty arthritis | |
| CN102727628B (en) | Chinese medicinal composition for treating functional constipation through hilum therapy | |
| CN102488838A (en) | Traditional Chinese medicine composition used for treating viral myocarditis | |
| CN101628056B (en) | Compound composition for treating diabetic constipation | |
| CN1879783A (en) | A medicine for treating diabetes | |
| CN101642485B (en) | Application of medical composition containing astragalus root in preparing medicine for treating leucopenia and Henoch-Schonlein Purpura | |
| CN1041494C (en) | Chinese-medicinal powder and capsule for treating chronic ischemic heart disease | |
| CN1245197C (en) | Chinese medicine preparation for treating coronary heart disease and viral myocarditis | |
| CN101703660B (en) | Anti-aging medicament | |
| CN106581299B (en) | Traditional Chinese medicine composition for improving kidney qi deficiency of middle-aged and old people and application thereof | |
| CN1245199C (en) | Oral medicinal composition for treating diabetes | |
| CN1698869A (en) | Mind easing oral liquor with gen-seng and lily bulb | |
| CN1872186A (en) | Compound capsule of Chinese date kernel, and preparation method | |
| CN111529659A (en) | Traditional Chinese medicine composition for treating bradyarrhythmia and preparation method and application thereof | |
| CN1233416C (en) | Compound pepsin powder for treating child dyspepsia and its preparation method | |
| CN104689244A (en) | TCM (Traditional Chinese Medicine) pill for treating heart-spleen blood deficiency type VMC (Viral Myocarditis) and preparation method | |
| CN1253188C (en) | Medicine for treating hypertension and its preparing process | |
| CN104147317A (en) | Medicament for treating male infertility | |
| CN115645478B (en) | Traditional Chinese medicine composition for treating primary dysmenorrhea and preparation method thereof | |
| CN102727730B (en) | Traditional Chinese medicinal compound preparation for treating male infertility and its preparation method | |
| CN1899480A (en) | Chinese medicine preparation for changing diabetes II insulin resistance and sugar, fat metabolic disorder |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: LI DECHUN Free format text: FORMER OWNER: GE QIANG Effective date: 20110414 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 114014 NO. 19, SHUANGTAI ROAD, TIEXI DEVELOPMENT ZONE, ANSHAN CITY, LIAONING PROVINCE TO: 114014 NO. 19, SHUANGTAI ROAD, HIGH-TECH. INDUSTRIAL DEVELOPMENT ZONE (WEST ZONE), ANSHAN CITY, LIAONING PROVINCE |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20110414 Address after: 114014 No. 19, double Road, hi tech Industrial Development Zone, Anshan, Liaoning Patentee after: Li Dechun Address before: 114014, Shuang Lu 19, Tiexi Development Zone, Liaoning, Anshan Patentee before: Ge Qiang |
|
| ASS | Succession or assignment of patent right |
Owner name: LIAONING LIANGXIN (GROUP) DEFENG PHARMACEUTICAL CO Free format text: FORMER OWNER: LI DECHUN Effective date: 20140102 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 114014 ANSHAN, LIAONING PROVINCE TO: 114018 ANSHAN, LIAONING PROVINCE |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20140102 Address after: 114018 in the West Liaoning province Anshan high tech Industrial Development Zone, double Station Road No. 19 Patentee after: Liaoning Liangxin (Group) Defeng Pharmaceutical Co.,Ltd. Address before: 114014 No. 19, double Road, hi tech Industrial Development Zone, Anshan, Liaoning Patentee before: Li Dechun |
|
| ASS | Succession or assignment of patent right |
Owner name: SICHUAN TIANLIAN PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: LIAONING LIANGXIN (GROUP) DEFENG PHARMACEUTICAL CO., LTD. Effective date: 20150409 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 114018 ANSHAN, LIAONING PROVINCE TO: 620036 MEISHAN, SICHUAN PROVINCE |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20150409 Address after: 620036 Sichuan New District Economic Development Zone of Meishan Province Patentee after: SICHUAN TIANLIAN PHARMACEUTICAL Co.,Ltd. Address before: 114018 in the West Liaoning province Anshan high tech Industrial Development Zone, double Station Road No. 19 Patentee before: Liaoning Liangxin (Group) Defeng Pharmaceutical Co.,Ltd. |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20170613 Address after: 620020 5 camphor Road, Meishan Economic Development Zone, Sichuan, China Patentee after: SICHUAN DEFENG PHARMACEUTICAL CO.,LTD. Address before: 620036 Sichuan New District Economic Development Zone of Meishan Province Patentee before: SICHUAN TIANLIAN PHARMACEUTICAL Co.,Ltd. |
|
| TR01 | Transfer of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20060913 |